Back to Journals » Neuropsychiatric Disease and Treatment » Volume 2 » Issue 4

Atomoxetine: a novel treatment for child and adult ADHD

Authors Marcialee Ledbetter

Published 15 December 2006 Volume 2006:2(4) Pages 455—466

Marcialee Ledbetter

University of Oklahoma-Tulsa, Tulsa, OK, USA

Abstract: Attention deficit hyperactivity disorder (ADHD) is a common chronic condition with childhood onset that can continue into adulthood. Medication is a fundamental element in the management of this disorder. Atomoxetine is the newest nonstimulant medication approved by the United States Food and Drug Administration (FDA) for the treatment of ADHD. It is the only nonstimulant medication approved by the FDA for treatment of adult ADHD. Atomoxetine is a norepinephrine reuptake inhibitor that selectively inhibits the presynaptic norepinephrine transporter. A growing body of literature supports the use of atomoxetine both in children and adults with ADHD. This paper summarizes information from the literature about atomoxetine, including pharmacokinetics, pharmacodynamics, clinical trials, dosing, and side-effects.  

Keywords: atomoxetine, ADHD, review, nonstimulants

Download Article [PDF]